Age-related-macular-degeneration, treatmentBevacizumab, therapeutic useEconomic-implicationsHealth-policyRanibizumab, therapeutic useReimbursementThe article discusses research on the effectiveness of avastin for treating wet age-related macular degeneration (AMD) which could result to huge cost savings in Great...
The analysis included 624 patients randomized to Eylea (aflibercept, Regeneron), Avastin (bevacizumab, Genentech) or Lucentis (ranibizumab, Genentech). Based on 2015 wholesale acquisition costs, the cost of aflibercept 2 mg was $1,850, ranibiz...
This variation is likely to be even bigger now that monoclonal antibodies, such as cetuximab (Erbitux) and bevacizumab (Avastin), have been accepted as standard therapies to be added onto chemotherapy regimens. The study finished at the end of 2005, and so did not assess the impact of these ...
Biosimilars to originator bevacizumab (Avastin), such as bevacizumab-bvzr (Zirabev), can deliver substantial savings and/or expanded access to biologic therapy for patients with metastatic colorectal (mCRC) and non-squamous non-small cell lung cancer (mNSCLC). The objective of this study is to ex...
In light of these new data, the present study was conducted with the goal of evaluating the cost-effectiveness of olaparib plus bevacizumab for the treatment of the overall AOC patient population and for homologous recombination deficiency (HRD)-positive patients, patients with a breast cancer ...
DrSaltz' battle against the cost of cancer drugs began with the 2012 US FDA approval of aflibercept [Zaltrap] for colon cancer treatment, at a cost of about $US11000 per month. This price was more than double that of bevacizumab [ Avastin ], notes DrSaltz, although the two drugs seemed...
By law, Medicare cannot reject any treatment based upon cost. It will pay $55,000 for patients with advanced breast cancer to receive the chemotherapy drug Avastin, even though it extends life only an average of a month and a half; it will pay $40,000 for a 93-year-old man with term...
By law, Medicare cannot reject any treatment based upon cost. It will pay $55,000 for patients with advanced breast cancer to receive the chemotherapy drug Avastin, even though it extends life only an average of a month and a half; it will pay $40,000 for a 93-year-old man with term...
1 Zaltrap had been priced at an average of about $11,000 a month, while Avastin costs less than half that at around $5000 per month. Subsequently, Sanofi discounted the net cost of Zaltrap by 50% in the United States in response to market resistance.5 Amid concerns with the high cost ...
abundance of treatment options in the EU market. Its socioeconomic impact also refers to the fact that it partially affects male patients in maturity, much before their retirement age. This malignancy creates substantial shortening of survival and affects the working ability of an individual patient ...